No Data
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Cuts Target Price to $360
Beigene's commercialized products for multiple indications are included in the new version of the national medical insurance drug list.
Beigene (06160) announced that its self-developed anti-PD-1 antibody drug, Baizean (Tiragolumab injection), and BTK inhibitor, Baiyueze (Zebutini capsule), have added three new indications and one indication has been included in the National Medical Insurance Catalog; Luye Pharma's co-introduced product, Baituowei (Goserelin injection microspheres), has added one indication included in the National Medical Insurance Catalog; Amgen's authorized introduced product, Kyprolis (Carfilzomib for injection), has successfully been renewed. The National Medical Insurance Catalog will be officially implemented starting January 1, 2025. This time the company's products Baizean and Baiyueze.
Should You Be Excited About Amgen Inc.'s (NASDAQ:AMGN) 56% Return On Equity?
Wednesday Ends With Index Decline | Wall Street Today
AMGN Stock Down Despite Strong Data From Obesity Drug Study
RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $330
No Data
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
